Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter
Authors:
Open Access
- 10 February 2022
- journal article
- research article
- Published by SAGE Publications in Bladder Cancer
- Vol. 8 (2) , 113-117
Abstract
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.Keywords
This publication has 6 references indexed in Scilit:
- Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centreBJU International, 2021
- The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder CancerEuropean Urology, 2021
- Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of MaintenanceEuropean Urology, 2013
- A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin CEuropean Urology, 2007
- HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIALJournal of Urology, 2005
- Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancerBJU International, 2002